TY  - JOUR
AU  - Guisado-Vasco, P.
AU  - Arranz-Saez, R.
AU  - Canales, M.
AU  - Cánovas, A.
AU  - Garcia-Laraña, J.
AU  - García-Sanz, R.
AU  - Lopez, A.
AU  - López, J.L.
AU  - Llanos, M.
AU  - Moraleda, J.M.
AU  - Rodriguez, J.
AU  - Rayón, C.
AU  - Sabin, P.
AU  - Salar, A.
AU  - Marín-Niebla, A.
AU  - Morente, M.
AU  - Sánchez-Godoy, P.
AU  - Tomás, J.F.
AU  - Muriel, A.
AU  - Abraira, V.
AU  - Piris, M.A.
AU  - Garcia, J.F.
AU  - Montalban, C.
T1  - Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series
LA  - eng
PY  - 2012
SP  - 812
EP  - 819
T2  - Leukemia and Lymphoma
SN  - 1042-8194
VL  - 53
IS  - 5
AB  - The International Prognostic Score (IPS) is the most widely used system to date for identifying risk groups for the outcome of patients with advanced Hodgkin lymphoma, although important limitations have been recognized. We analyzed the value of the IPS in a series of 311 patients with advanced classical Hodgkin lymphoma (cHL) (Ann Arbor stage III, IV or stage II with B symptoms and/or bulky masses) treated with first-line chemotherapy including adriamycin (adriamycin, bleomycin, vinblastine, dacarbazine [ABVD] or equivalent variants). In univariate and multivariate analyses, stage IV disease and age ≥ 45 years were the only factors with independent predictive significance for overall survival (OS) (p = 0.002 and p < 0.001, respectively). Stage IV was still significant for freedom from progression (FFP) (p = 0.001) and age ≥ 45 years was borderline significant (p = 0.058). IPS separates prognostic groups, as in the original publication, but this is mainly due to the high statistical significance of stage IV and age ≥ 45 years. Moreover, the combination of these two factors enables a simpler system to be constructed that separates groups with different FFP and OS. In conclusion, in our series, stage IV and age ≥ 45 years are the key prognostic factors for the outcome of advanced cHL. © 2012 Informa UK, Ltd.
DO  - 10.3109/10428194.2011.635861
UR  - https://portalciencia.ull.es/documentos/5e7359642999520cdba39927
DP  - Dialnet - Portal de la Investigación
ER  -